Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 1;35(11):875–887. doi: 10.1089/jir.2014.0210

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Judy Ly et al. 2015; Published by Mary Ann Liebert, Inc.

This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

PMC Copyright notice

FIG. 6. — Difference in plasma IL-6 levels and ROS markers pre- and post-GSH supplementation. Sandwich ELISA was performed to compare the cytokine levels between pre-supplementation (V1) and post-supplementation (V3). Assay of cytokines showed a significant decrease in the levels of IL-6 in plasma samples collected from the lGSH-treatment group. There was no significant difference between the levels of IL-6 from the placebo group when comparing visit 1 and visit 3 (A). Data represent mean±SE, *P<0.05 when comparing pre- and post-supplementation levels within placebo or lGSH group. MDA assay was performed to compare the levels of MDA, a byproduct of lipid peroxidation, between pre-supplementation (V1) and post-supplementation (V3). Assay of MDA showed that there was no significant difference between the levels of MDA in plasma (B), RBC (D), and monocytes (F) from the placebo group when comparing visit 1 and visit 3. The levels of MDA in plasma (C), RBC (E), and monocytes (G) of the lGSH-treatment group significantly decreased after 13 weeks of supplementation. Data represent mean±SE, **P<0.005 when comparing pre- and post-supplementation levels within placebo or lGSH group. Flow cytometry analysis of CellROX mean intensity, an indicator of ROS production, was completed to compare the levels of ROS production in different cell populations between pre-supplementation (V1) and post-supplementation (V3). Flow cytometry analysis of ROX showed that there was no significant difference between the median of ROX mean intensity CD4⁺ T-cells (H), CD8⁺ T-cells (J), and CD14⁺cells/monocytes (L) from the placebo group when comparing visit 1 and visit 3. Median of ROX mean intensity in CD4⁺ T-cells (I), CD8⁺ T-cells (K), and CD14⁺cells/monocytes (M) from the lGSH-treatment group significantly decreased after 13 weeks of supplementation. Data represent medians with range, *P<0.05 when comparing pre- and post-supplementation levels within placebo or lGSH group using the non-parametric version of the t-test, Mann–Whitney test.

FIG. 6. — Difference in plasma IL-6 levels and ROS markers pre- and post-GSH supplementation. Sandwich ELISA was performed to compare the cytokine levels between pre-supplementation (V1) and post-supplementation (V3). Assay of cytokines showed a significant decrease in the levels of IL-6 in plasma samples collected from the lGSH-treatment group. There was no significant difference between the levels of IL-6 from the placebo group when comparing visit 1 and visit 3 (A). Data represent mean±SE, *P<0.05 when comparing pre- and post-supplementation levels within placebo or lGSH group. MDA assay was performed to compare the levels of MDA, a byproduct of lipid peroxidation, between pre-supplementation (V1) and post-supplementation (V3). Assay of MDA showed that there was no significant difference between the levels of MDA in plasma (B), RBC (D), and monocytes (F) from the placebo group when comparing visit 1 and visit 3. The levels of MDA in plasma (C), RBC (E), and monocytes (G) of the lGSH-treatment group significantly decreased after 13 weeks of supplementation. Data represent mean±SE, **P<0.005 when comparing pre- and post-supplementation levels within placebo or lGSH group. Flow cytometry analysis of CellROX mean intensity, an indicator of ROS production, was completed to compare the levels of ROS production in different cell populations between pre-supplementation (V1) and post-supplementation (V3). Flow cytometry analysis of ROX showed that there was no significant difference between the median of ROX mean intensity CD4⁺ T-cells (H), CD8⁺ T-cells (J), and CD14⁺cells/monocytes (L) from the placebo group when comparing visit 1 and visit 3. Median of ROX mean intensity in CD4⁺ T-cells (I), CD8⁺ T-cells (K), and CD14⁺cells/monocytes (M) from the lGSH-treatment group significantly decreased after 13 weeks of supplementation. Data represent medians with range, *P<0.05 when comparing pre- and post-supplementation levels within placebo or lGSH group using the non-parametric version of the t-test, Mann–Whitney test.